Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.59 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3551408 | 1.00 | F10 (0.59) | F10F2KMT2ALMNAMAPK1 | |
| SCHEMBL3553304 | 0.88 | F10 (0.59) | F10F2KMT2ALMNAMAPK1 | |
| SCHEMBL3548699 | 0.88 | F10 (0.59) | F10F2KMT2ALMNAMAPK1 | |
| SCHEMBL3553423 | 0.87 | F10 (0.55) | F10F2KMT2ALMNAMAPK1 | |
| SCHEMBL3554161 | 0.83 | F10 (0.56) | F10F2KMT2ALMNAMAPK1 | |
| SCHEMBL13436096 | 0.83 | F10 (0.56) | F10F2KMT2ALMNAMAPK1 | |
| SCHEMBL3552201 | 0.81 | F10 (0.46) | F10MAPK1TSHR | |
| SCHEMBL13436103 | 0.81 | F10 (0.46) | F10MAPK1TSHR | |
| SCHEMBL3309272 | 0.80 | F10 (0.51) | F10F2KMT2ALMNAMAPK1 | |
| SCHEMBL3309265 | 0.80 | F10 (0.51) | F10F2KMT2ALMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678917-B2 | Factor Xa inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678917-B2 | Factor Xa inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678917-B2 | Factor Xa inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| WO-2007025949-A1 | NOVEL CYCLOALKANE CARBOXAMIDES AS FACTOR XA INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049587-A1 | Factor Xa inhibitors | HOFFMANN-LA ROCHE INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049587-A1 | Factor Xa inhibitors | HOFFMANN-LA ROCHE INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049587-A1 | Factor Xa inhibitors | HOFFMANN-LA ROCHE INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049587-A1 | Factor Xa inhibitors | F12, F11, F10 | F10 3/4885F2 4/4885KMT2A 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.